Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol ; volume:9 ; number:1 ; day:22 ; month:11 ; year:2023 ; pages:1-10 ; date:12.2023
Pilot and feasibility studies ; 9, Heft 1 (22.11.2023), 1-10, 12.2023
- Creator
-
Dissanayaka, Nadeeka
Pourzinal, Dana
Byrne, Gerard J.
Yang, Jihyun
McMahon, Katie L.
Pontone, Gregory M.
O’Sullivan, John D.
Adam, Robert
Littleford, Roberta
Chatfield, Mark
Lehn, Alexander
Mari, Zoltan
Bakker, Arnold
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40814-023-01406-y
- URN
-
urn:nbn:de:101:1-2024021211094937052908
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dissanayaka, Nadeeka
- Pourzinal, Dana
- Byrne, Gerard J.
- Yang, Jihyun
- McMahon, Katie L.
- Pontone, Gregory M.
- O’Sullivan, John D.
- Adam, Robert
- Littleford, Roberta
- Chatfield, Mark
- Lehn, Alexander
- Mari, Zoltan
- Bakker, Arnold
- SpringerLink (Online service)
Other Objects (12)
Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Parkinson
Parkinson
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Parkinson
Parkinson
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease
Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study
Parkinson
Parkinson
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
Precision medicine in Parkinson’s disease: emerging treatments for genetic Parkinson’s disease
Nutraceuticals in Parkinson’s Disease
Redefinition of Parkinson’s Disease
Neuroplasticity in Parkinson’s disease